Pair page
Cagrilintide with Tesofensine
Mechanism-tag overlap and published literature for Cagrilintide and Tesofensine, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
long-acting-amylin-analog
triple-monoamine-reuptake-inhibitor
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Cagrilintide and Tesofensine have published these mechanism-level observations. Not a co-administration recommendation.
Long-acting amylin analogue. Mechanistically orthogonal to tesofensine: amylin-receptor satiety signaling versus central monoaminergic. Theoretical complementarity (different appetite circuits, different cardiovascular profiles) but no published clinical data on the combination. Sequential use is more conservative than concurrent.
Quick facts
Cagrilintide
Tesofensine
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| — | Cagrilintide | ClinicalTrials.gov. REDEFINE 1 (NCT05567796) and REDEFINE 2 (NCT05394519). Novo Nordisk CagriSema Phase 3 program. | human trial, Phase 3 |
| 2023 | Cagrilintide | Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730. | human trial, Phase 2 |
| 2023 | Cagrilintide | Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. (Comparator.) PMID 37366315 | human trial, Phase 2 |
| 2021 | Cagrilintide | Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. | human trial, Phase 2 |
| 2025 | Cagrilintide | Garvey WT, Frias JP, Jastreboff AM, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025. DOI: 10.1056/NEJMoa2502081. | human trial |
| 2025 | Cagrilintide | Davies MJ, Frias JP, Jastreboff AM, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med. 2025. PMID: 40544432. DOI: 10.1056/NEJMoa2502082. PMID 40544432 | human trial |
| 2022 | Cagrilintide | Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024. (Comparator.) PMID 35658024 | human trial |
| 2021 | Cagrilintide | Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. (Comparator.) PMID 33567185 | human trial |
| 2025 | Cagrilintide | Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025. (Novo Nordisk next-generation successor to CagriSema.) | human trial, Phase 1 |
| 2021 | Cagrilintide | Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286)… PMID 33894838 | human trial, Phase 1 |
| 2018 | Cagrilintide | Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. Br J Pharmacol. 2018;175(1):3-17. PMID: 29059473. PMID 29059473 | review |
| 2021 | Cagrilintide | Kruse T, Dahl K, Frigeri P, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. Endocrinology. 2021;162(6):bqab057. PMID: 33727283. PMID 33727283 | research article |
| 2026 | Tesofensine | Saniona AB. Tesomet — Pipeline. saniona.com/pipeline/tesomet. Accessed April 2026. (Phase 2b PWS and hypothalamic obesity trials voluntarily paused due to funding limitations; not safety/efficacy.) | human trial, Phase 2 |
| 2008 | Tesofensine | Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Nov 29;372(9653):1906-1913. doi: 10.1016/S0140-… PMID 18950853 | human trial, Phase 2 |
| — | Tesofensine | ClinicalTrials.gov. NCT03845075 — Randomized Controlled Trial of Tesomet in Adults With Hypothalamic Obesity. NCT03149445 — Phase 2a Tesomet in Prader-Willi Syndrome. NCT00394667 — Effect of Tesofensine on Weight Reduction in Patients With Obesity. clinicaltrials.gov. | human trial, Phase 2 |
| 2022 | Tesofensine | Huynh KD, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S, Magkos F, Aharaz A, Edsberg B, Tfelt-Hansen J, Astrup AV, Feldt-Rasmussen U. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022 Apr 28;186(6):687-700. doi: 10.1530… PMID 35294397 | human trial |
| 2009 | Tesofensine | Expression of concern—Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Feb 28;373(9665):719. doi: 10.1016/S0140-6736(09)60433-5. PMID: 19249626. PMID 19249626 | human trial |
| 2007 | Tesofensine | Hauser RA, Salin L, Juhel N, Konyago VL, et al. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov Disord. 2007 Feb 15;22(3):359-365. doi: 10.1002/mds.21258. | human trial |
| 2009 | Tesofensine | Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2009 Oct;10(10):1105-16. PMID: 19777399. PMID 19777399 | human study |
| 2008 | Tesofensine | Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring). 2008 Jun;16(6):1363-9. PMID: 18356831. PMID 18356831 | human study |
| 2008 | Tesofensine | Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T; ADVANS Study Group. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol. 2008 May;65(5):577-83.… PMID 18474731 | human study |
| 2013 | Tesofensine | Bentzen BH, Grunnet M, Hyveled-Nielsen L, Sundgreen C, Lassen JB, Hansen HH. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring). 2013 May;21(5):985-92. doi: 10.1002/oby.20122.… | preclinical, in vivo |
| 2010 | Tesofensine | Axel AM, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of α1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010 May;35(7):1464-76. d… | preclinical, in vivo |
| 2010 | Tesofensine | Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AM, Raben A, Mikkelsen JD. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur… | preclinical, in vivo |
Related pair pages
More research context
Frequently asked
Have Cagrilintide and Tesofensine been studied together?
Researchers have published mechanistic-level co-administration discussion of Cagrilintide and Tesofensine. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Cagrilintide and Tesofensine share?
Cagrilintide and Tesofensine do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Cagrilintide and Tesofensine?
Cagrilintide: Investigational; CagriSema under review. Tesofensine: Investigational. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Cagrilintide and Tesofensine?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Cagrilintide profile and the Tesofensine profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026